Intensive early HIV treatment in newborns to aim for remission
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Babies must start the study within 48 hours after birth.
- The baby must be born at 37 weeks or later and weigh at least 2 kilograms.
- The mother must have HIV infection around pregnancy (either suspected at delivery or confirmed by blood tests).
- The baby must be able to take HIV medicine by mouth or feeding tube.
- The mother must agree (give consent) for the baby’s participation in the study steps.
- The family must be able to follow frequent clinic visits and testing schedules for months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different HIV medicines in children and teenagers to find safer, more effective options. It aims to improve viral suppression and overall health for young people living with HIV.
This trial tests a new combination of HIV medicines for children and teenagers under 18 who weigh at least 35 kilograms (about 77 pounds). It aims to see if this treatment is safe and effective for young people who have not been treated before or who are already on a stable HIV treatment.
This study follows pregnant women with viral infections (like HIV or hepatitis) and their babies to see how the infection and treatments affect both. It aims to improve care for mothers and children.
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
This study tests whether a combination of two long-acting HIV medications (cabotegravir and rilpivirine), given as shots every month, is safe and works well for pregnant women who are already taking this treatment. It aims to keep the mother's HIV under control and protect the baby.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Hear when a new HIV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.